Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | FER | P16591 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | CCKAR | P32238 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7546466 | 1.00 | CCKBR (0.52) | CCKBRMEN1ALDH1A1KMT2ABRPF1 | |
| SCHEMBL18315504 | 0.81 | NOTCH1 (0.48) | CCKBRMEN1ALDH1A1KMT2AMAOA | |
| SCHEMBL15629495 | 0.81 | NOTCH1 (0.48) | CCKBRMEN1ALDH1A1KMT2AMAOA | |
| SCHEMBL14169793 | 0.81 | CCKBR (0.50) | CCKBRMEN1ALDH1A1KMT2ABRPF1 | |
| SCHEMBL7546890 | 0.80 | CHRM1 (0.40) | CCKBRMEN1ALDH1A1KMT2ABRPF1 | |
| SCHEMBL7546878 | 0.80 | CHRM1 (0.40) | CCKBRMEN1ALDH1A1KMT2ABRPF1 | |
| SCHEMBL7552256 | 0.80 | MEN1 (0.41) | CCKBRMEN1ALDH1A1KMT2ABRPF1 | |
| SCHEMBL7552264 | 0.80 | MEN1 (0.41) | CCKBRMEN1ALDH1A1KMT2ABRPF1 | |
| SCHEMBL18315499 | 0.79 | MEN1 (0.50) | CCKBRMEN1ALDH1A1KMT2ACCKAR | |
| SCHEMBL15629440 | 0.79 | MEN1 (0.50) | CCKBRMEN1ALDH1A1KMT2ACCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0934282-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015535-A1 | 1,4-BENZODIAZEPINONES AND THEIR USES AS CCK ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CCKBR 2/4885MEN1 2261/4885ALDH1A1 1169/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | CCKBR 2/4885MEN1 2261/4885ALDH1A1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.